Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome.
ANCA
end-stage renal disease
glomerulonephritis
microscopic polyangiitis
rituximab
vasculitis
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
20
01
2020
accepted:
25
05
2020
entrez:
10
2
2021
pubmed:
11
2
2021
medline:
11
2
2021
Statut:
epublish
Résumé
Although rapidly progressive glomerulonephritis is the main renal phenotype of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), slow renal disease progression is sometimes observed. These forms have been rarely discussed; we analysed their prevalence, clinico-pathological characteristics and outcome. We screened patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis followed at seven referral centres and selected those with estimated glomerular filtration rate (eGFR) reduction <50% over a 6-month period preceding diagnosis. Data regarding patient features and response to treatment were retrieved. Of 856 patients, 41 (5%) had slowly progressive renal AAV. All had MPA and all but one was P-ANCA/myeloperoxidase (MPO) ANCA-positive. At diagnosis, the median age was 70 years [interquartile range (IQR) 64-78] and extra-renal manifestations were absent or subclinical (interstitial lung lesions in 10, 24%). The median (IQR) eGFR was 23 mL/min/1.73 m AAV may present with slow renal disease progression; this subset is hallmarked by advanced age at diagnosis, positive MPO-ANCA, subclinical interstitial lung lesions and chronic damage at kidney biopsy. Partial renal recovery may occur following immunosuppression.
Sections du résumé
BACKGROUND
BACKGROUND
Although rapidly progressive glomerulonephritis is the main renal phenotype of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), slow renal disease progression is sometimes observed. These forms have been rarely discussed; we analysed their prevalence, clinico-pathological characteristics and outcome.
METHODS
METHODS
We screened patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis followed at seven referral centres and selected those with estimated glomerular filtration rate (eGFR) reduction <50% over a 6-month period preceding diagnosis. Data regarding patient features and response to treatment were retrieved.
RESULTS
RESULTS
Of 856 patients, 41 (5%) had slowly progressive renal AAV. All had MPA and all but one was P-ANCA/myeloperoxidase (MPO) ANCA-positive. At diagnosis, the median age was 70 years [interquartile range (IQR) 64-78] and extra-renal manifestations were absent or subclinical (interstitial lung lesions in 10, 24%). The median (IQR) eGFR was 23 mL/min/1.73 m
CONCLUSIONS
CONCLUSIONS
AAV may present with slow renal disease progression; this subset is hallmarked by advanced age at diagnosis, positive MPO-ANCA, subclinical interstitial lung lesions and chronic damage at kidney biopsy. Partial renal recovery may occur following immunosuppression.
Identifiants
pubmed: 33564436
doi: 10.1093/ckj/sfaa139
pii: sfaa139
pmc: PMC7857823
doi:
Types de publication
Journal Article
Langues
eng
Pagination
332-340Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.
Références
Kidney Int. 2002 Jan;61(1):80-9
pubmed: 11786087
J Am Soc Nephrol. 2010 Oct;21(10):1628-36
pubmed: 20616173
Clin Exp Immunol. 2011 May;164 Suppl 1:14-6
pubmed: 21447124
Arthritis Rheumatol. 2016 Mar;68(3):713-23
pubmed: 26474081
Nephrol Dial Transplant. 2014 Sep;29(9):1764-9
pubmed: 24748668
Am J Kidney Dis. 2014 Feb;63(2):227-35
pubmed: 24183110
Am J Kidney Dis. 2006 May;47(5):770-9
pubmed: 16632015
Ann Rheum Dis. 2009 Dec;68(12):1827-32
pubmed: 19054820
J Nephrol. 2016 Apr;29(2):195-201
pubmed: 25986390
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Autoimmun Rev. 2014 Jul;13(7):723-9
pubmed: 24657897
N Engl J Med. 1997 Nov 20;337(21):1512-23
pubmed: 9366584
Intern Med. 1999 Aug;38(8):679-82
pubmed: 10440508
Intern Med. 2018 Jun 15;57(12):1757-1762
pubmed: 29269683
Intern Med. 2002 Jun;41(6):458-62
pubmed: 12135179
Am J Nephrol. 2018;48(6):465-471
pubmed: 30472700
Intern Med. 2002 Jun;41(6):418-9
pubmed: 12135171
Nephron. 2015;129(4):276-82
pubmed: 25871843
Ann Rheum Dis. 2007 Feb;66(2):222-7
pubmed: 16901958
Semin Respir Crit Care Med. 2018 Aug;39(4):459-464
pubmed: 30404112
Eur Respir J. 2010 Jul;36(1):116-21
pubmed: 19926741
Autoimmun Rev. 2013 Feb;12(4):477-82
pubmed: 22921791
Autoimmun Rev. 2010 Oct;9(12):812-9
pubmed: 20656070
Eur Respir J. 2011 Jun;37(6):1503-13
pubmed: 21071471
Rheum Dis Clin North Am. 2010 Aug;36(3):507-26
pubmed: 20688247
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
J Clin Invest. 2002 Oct;110(7):955-63
pubmed: 12370273